Description
The APOE extremes whole genome sequencing (WGS) study entails Alzheimer’s disease (AD) case-control association analysis using an age extremes sampling approach stratified by APOE genotype, comparing younger onset AD cases against older cognitively normal controls. We queried the National Alzheimer’s Coordinating Center database to select individuals that lacked sequencing data and matched the following criteria: APOE ε4/ε4 or ε3/ε4 AD cases with age at onset ≤ 65 years, APOE ε4/ε4 controls with age at last assessment ≥ 75 years, or APOE ε3/ε4 controls with age at last assessment ≥ 80 years. DNA samples were provided by the National Cell Repository of Alzheimer’s Disease.
NACC Genentech WGS sample set. WGS was performed at Illumina. PCR-amplified, paired-end Illumina libraries were generated then underwent paired-end sequencing on an Illumina HiSeq 2000.
Knight-ADRC APOE-extreme WGS sample set (to be released with R5 WGS). WGS was performed at Illumina. PCR-amplified, paired-end Illumina libraries were generated then underwent paired-end sequencing on an Illumina HiSeq 2000.
Goate APOE extremes WGS sample set (subset of ADSP FUS 1). WGS was performed at The American Genome Center, Uniformed Services University of the Health Sciences. PCR-free, 150 bp paired-end Illumina libraries were generated then underwent paired-end sequencing on an Illumina HiSeq X.